Paper Details
- Home
- Paper Details
Treatment of metastatic colorectal carcinoma with a combination of fluorouracil and recombinant interferon alfa-2b: preliminary data of a phase II study.
Author: BraumannD, BuggischP, Crone-MünzebrockW, DrescherS, HoffmanR, KleebergU R, MüllerleileU, PlatzD, SchmiegelW H, WehH J
Original Abstract of the Article :
From March 1990 to January 1991 52 previously untreated patients with metastatic colorectal carcinoma were enrolled in a phase II study with the combination of interferon alfa-2b and fluorouracil (5-FU). 5-FU 750 mg/m2 per day was administered as continuous infusion for 5 days, then weekly in a dose...See full text at original site
Dr.Camel's Paper Summary Blogラクダ博士について
ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。
* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。
引用元:
https://pubmed.ncbi.nlm.nih.gov/1557644
データ提供:米国国立医学図書館(NLM)
A Phase II Study: Exploring the Efficacy of Fluorouracil and Interferon Alfa-2b in Metastatic Colorectal Carcinoma
Metastatic colorectal carcinoma, a serious and often challenging condition, demands innovative therapeutic approaches. This phase II study investigates the efficacy and toxicity of a combination therapy involving fluorouracil (5-FU) and recombinant interferon alfa-2b in treating patients with metastatic colorectal carcinoma. The researchers sought to determine the effectiveness of this regimen and evaluate its potential benefits and risks.
Fluorouracil and Interferon Alfa-2b: A Potential Treatment for Metastatic Colorectal Carcinoma
The study revealed that the combination therapy of 5-FU and interferon alfa-2b demonstrated promising efficacy in treating metastatic colorectal carcinoma, with a partial remission rate of 31%. However, the regimen also exhibited significant toxicity, with leukopenia, diarrhea, mucositis, and septic complications being the most common adverse events. These findings highlight the need for further research to optimize the schedule and dosage of the drugs to improve the therapeutic index.
Navigating the Complex Landscape of Cancer Treatment: Balancing Efficacy and Safety
This research underscores the complex challenges of cancer treatment, where balancing efficacy and safety is paramount. The study highlights the potential of combination therapies for treating metastatic colorectal carcinoma, while emphasizing the importance of careful monitoring and management of toxicity. Just as a desert traveler must carefully balance their water supply to survive, oncologists must carefully navigate the delicate balance between treatment efficacy and patient safety.
Dr. Camel's Conclusion
This phase II study, like a camel caravan venturing into uncharted territory, explores the potential of a combination therapy for metastatic colorectal carcinoma. While the journey reveals promising possibilities, it also highlights the challenges and risks associated with this approach. The researchers, like skilled navigators, carefully document the results, providing valuable insights for future research and guiding the path towards more effective and safe cancer treatments.
Date :
- Date Completed 1992-05-01
- Date Revised 2018-11-30
Further Info :
Related Literature
English
This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.